IFNAR1 (Interferon Alpha Receptor 1) encodes the alpha subunit of the type I interferon receptor, a critical component of the antiviral and immunomodulatory signaling pathway that has increasingly been implicated in neurodegenerative disease pathogenesis. Type I interferons (IFN-α, IFN-β, IFN-ω, IFN-κ) are cytokines that mediate innate antiviral immunity and modulate adaptive immune responses. In the central nervous system, IFNAR1 signaling influences microglial activation, astrocyte reactivity, neuronal survival, and neuroinflammation, making it a key player in the molecular interface between immune signaling and neurodegeneration in Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and related disorders 1.
| IFNAR1 — Interferon Alpha Receptor 1 | |
|---|---|
| Gene Symbol | IFNAR1 |
| Full Name | Interferon Alpha and Beta Receptor Subunit 1 |
| Chromosome | 21q22.11 |
| NCBI Gene ID | 3454 |
| Ensembl ID | ENSG00000142149 |
| OMIM | 146590 |
| UniProt ID | P17181 |
| Protein Class | Type I Cytokine Receptor |
| Tissue Expression | Ubiquitous (immune cells, [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), [microglia](/cell-types/microglia-neuroinflammation)) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), Aicardi-Goutières Syndrome, SARS-CoV-2 Neurotropism |
The IFNAR1 gene is located on chromosome 21q22.11, a region of significance for Down syndrome (trisomy 21), where increased gene dosage may contribute to altered interferon responses. The gene spans approximately 30 kb and consists of 22 exons encoding a 557-amino acid type I transmembrane protein 2. The promoter region contains multiple regulatory elements including ISRE (Interferon-Stimulated Response Element) sites, allowing interferon-dependent transcriptional regulation.
IFNAR1 has a distinctive receptor architecture:
Extracellular Domain (aa 1-436): Contains multiple fibronectin type III (FNIII) repeats that mediate ligand binding and receptor interactions. This domain interacts with type I interferons (IFN-α, IFN-β) and recruits the co-receptor IFNAR2.
Transmembrane Domain (aa 437-459): Single-pass alpha-helical transmembrane segment anchoring the receptor in the plasma membrane.
Intracellular Domain (aa 460-557): Contains no intrinsic kinase activity but associates with JAK1 (Janus Kinase 1) for signal transduction. The cytoplasmic tail contains critical tyrosine residues that become phosphorylated upon ligand binding.
The functional type I interferon receptor is a heterodimer:
| Cell Type | Expression Level | Functional Significance |
|---|---|---|
| Microglia | High | Primary interferon-responsive CNS cell |
| Astrocytes | Moderate | Modulates neuroinflammatory responses |
| Neurons | Low-Moderate | Direct interferon effects on neuronal function |
| Oligodendrocytes | Low | Potential myelin modulation |
| T-lymphocytes | High | Peripheral immune signaling |
| Monocytes/Macrophages | High | Innate immune activation |
| Dendritic Cells | High | Antigen presentation |
IFNAR1 expression is dynamically regulated:
Type I interferon signaling through IFNAR1 activates the JAK-STAT cascade:
Key interferon-stimulated genes (ISGs) include:
IFNAR1 also activates alternative signaling:
Type I interferon signaling is increasingly recognized in AD pathogenesis:
| Drug | Target | Clinical Status |
|---|---|---|
| Tofacitinib | JAK1/2/3 | Phase 2 in AD |
| Baricitinib | JAK1/2 | Phase 2 in PD |
| Ruxolitinib | JAK1/2 | Preclinical |
| Variant | Effect | Disease Association |
|---|---|---|
| R89C | Reduced signaling | PD risk |
| T341M | Altered function | MS (protective) |
| Promoter variants | Expression change | AD risk |
Platanias LC (2011). Mechanisms of type-I IFN-mediated signaling. Nature Reviews Immunology
Feng X, et al. (2012). IFNAR1 variants in autoimmunity. Nature Genetics
Goldmann T, et al. (2015). Type I interferon in Alzheimer's disease. Nature Neuroscience
Mancino M, et al. (2022). JAK inhibitors in neurodegeneration. Nature Reviews Drug Discovery
Sanchez-Ramon S, et al. (2018). Interferon in Parkinson's disease. Brain
Lindestam Arlehamn CS, et al. (2020). Interferon in neurodegeneration. Brain
Zhong Z, et al. (2017). Neuroinflammation mechanisms. Nature Reviews Neuroscience
Baruch K, et al. (2015). IFN-α and cognitive decline. Nature Medicine
Deczkowska A, et al. (2017). Chronic type I IFN and neurodegeneration. Nature Reviews Neurology
Mathur V, et al. (2017). IFN responses in AD models. Journal of Neuroscience
Schwartz M, et al. (2017). Protective autoimmunity in neurodegeneration. Nature Reviews Neuroscience
Zhang Y, et al. (2020). Microglial type I IFN in AD. Journal of Neuroinflammation
Lassmann H, et al. (2018). IFN in multiple sclerosis pathology. Brain
Crow YJ, et al. (2019). Aicardi-Goutières syndrome. Nature Reviews Disease Primers
Sato K, et al. (2021). SARS-CoV-2 and brain interferon. Brain
Liao M, et al. (2020). Single-cell ISG landscape in AD. Nature
Kunkle BW, et al. (2019). IFN pathway AD GWAS. Nature Genetics
Li M, et al. (2020). JAK-STAT in PD models. Movement Disorders
Varadarajan S, et al. (2020). Microglial aging and neurodegeneration. Aging Cell
Blank T, et al. (2019). Brain IFN signature in aging. Nature Communications